Company news
Erasca, Inc. news in 2022
Erasca, Inc.'s news releases, calls and decks from 2022, newest first.
Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
December 19, 2022
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
December 12, 2022
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
December 8, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
November 29, 2022
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
November 8, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
October 19, 2022
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
October 11, 2022
Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
September 25, 2022
Erasca to Present at the Morgan Stanley Global Healthcare Conference
September 8, 2022
Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials
September 6, 2022
Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors
August 23, 2022
Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers
August 22, 2022
Erasca Reports Second Quarter 2022 Financial Results and Business Updates
August 10, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination
July 17, 2022
Erasca to Present at the 2022 Jefferies Healthcare Conference
June 2, 2022
Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers
June 1, 2022
Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments
May 24, 2022
Erasca Reports First Quarter 2022 Financial Results and Business Updates
May 11, 2022
Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
May 2, 2022
Erasca Appoints Jean Liu to its Board of Directors
April 26, 2022
Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting
April 11, 2022
Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway
April 5, 2022
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates
March 23, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination
March 9, 2022
Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting
March 7, 2022
Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day
February 2, 2022
Erasca Strengthens Leadership Team with Two Key Executive Appointments
January 17, 2022
Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Decks in 2022
- Investor Presentation (December 2022)
Investor deck · 81 slides · Dec 9, 2022
- Investor Day (September 2022)
Investor day · 62 slides · Sep 7, 2022